Rocket Pharmaceuticals (RCKT) Highlights Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 'Process B' for Fanconi Anemia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Rocket Pharmaceuticals (RCKT) Highlights Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 'Process B' for Fanconi Anemia
December 11, 2019 5:59 AM EST
Rocket Pharmaceuticals, Inc. (NASDAQ:... More
December 10, 2019 4:02 PM EST
Rocket... More
December 9, 2019 8:02 AM EST
Chardan Capital Markets analyst Geulah Liveshits raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $33.00 (from $30.00) while maintaining a Buy rating.
The analyst commented, "On 8 November, Rocket Pharmaceuticals presented preliminary data on ex vivo lentiviral gene therapy RP-L102 for Fanconi anemia (FA), manufactured with commercial-grade "Process B", demonstrating (1) 2-3x higher product vector copy numbers (VCNs) vs. Process A product, and (2) signals of engraftment in patients at 6 months. The data, presented in a poster at the American Society of Hematology (ASH) 2019 Annual... More
December 9, 2019 7:02 AM EST
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announces preliminary data from its Phase 1/2 clinical trial of RP-L201, the Companys lentiviral vector... More
December 6, 2019 8:16 AM EST
Baird analyst Madhu Kumar raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $41.00 (from $30.00) while maintaining a Outperform rating.
Adds to Fresh Pick list.
The analyst comments "Prior to Rocket Pharmaceuticals' (RCKT) data release at the American Society... More
